Effect inhibitor leukotriene generation airway responses allergen challenge asthmatic patients effect single oral dose mg zileuton specific inhibitor early late airway responses allergen randomised double blind placebo trial subjects atopic asthma Leukotriene generation vivo urinary leukotriene LT excretion vivo calcium whole blood production Zileuton inhibited ex vivo production reduced urinary excretion half trend early asthmatic response day zileuton treatment statistical significance zileuton reduction maximum fall early asthmatic response reduction urinary excretion reduction generation ex vivo significant change allergen late asthmatic response increase airway responsiveness antigen results support hypothesis cysteinyl leukotrienes role allergen early asthmatic response complete vivo inhibition significant reduction airway response challenge 